| 영문 | rheumatoid factor | 한글 | 류마티스 인자 |
|---|---|---|---|
| 설명 | IgG의 Fc부위에 있는 항원결정인자에 대한 항체로서 전형적인 또는 확실한 류마티스관절염(rheumatoid arthritis) 환자의 80%에서 발견된다. 류마티스 인자는 IgM, IgG, IgA중 하나가 될 수 있으나 주로 IgM이다. 소아류마티스관절염(juvenile rheumatoid arthritis: 소아기에 발생하는 류마티스관절염)을 비롯한, 다른 결합조직병이나 감염병에도 나타날 수 있다 |
||
| 영문 | growth factor | 한글 | 성장인자 |
|---|---|---|---|
| 설명 | 세포의 분화 및 성장에 관여하는 단백질. 성장인자는 정상 세포주기에 필수적이기 때문에 동물의 생명에 중대한 요소가 된다. 무엇보다도 성장인자는 태아의 발육을 조정하고 조직의 유지 및 보수에 중대한 역할을 하며, 혈구의 생성을 자극한다. 또한 암의 진행과정에도 관여한다. |
||
| 영문 | risk factor | 한글 | 위험인자 |
|---|---|---|---|
| 설명 | 국제방사선방호위원회(ICRP)가 1977년 권고에서 방사선방호의 목적으로 채택한 지수로, 단위선량(1 Sv)당 확률적 영향의 발생확률을 추정하여 나타낸 것이다. 생식선 선량에 대한 유전적영향의 발생률(4×10－3/Sv)이나 적색골수선량에 대한 백혈병 발생률(2×10－3/Sv)등 외에 뼈, 허파, 갑상샘, 젖샘, 기타 조직의 위험지수를 측정하여, 확률적 영향의 전신에 있어서 치사위험지수의 합계를 16.5×10－3/Sv로 하였다. 그후 ICRP는 1990년 권고에서 대상이 되는 조직과 장기를 추가하고, 수치 개정을 하면서 명칭도 각목적확률지수라고하였다. 이 권고에 의하면, 치사적 확률적 영향의 확률지수의 합계는, 일반인에 있어 60.0×10－3/Sv이다. |
||
| CF | calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ... |
|---|---|
| EF | ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e... |
| PF | pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid... |
| PAF | paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl... |
| SF | Sabin-Feldman [test]; safety factor; salt-free; scarlet fever; screen film; seminal fluid; serosal f... |
| CNF1 | Cytotoxic Necrotizing Factor 1 |
|---|---|
| CNF1 | Cytotoxic necrotizing factor type 1 |
| CNF | Cytotoxic necrotizing factor |
| NKCF | NK cytotoxic factor |
| NKCF | Natural killer cytotoxic factor |
IGF-II : insulin like growth factor-II의 약자. 많은 장기와 조직에 작용하여 단백 합성과 DNA, RNA의 합성을 증가시켜 세포의 수와 양을 증가
| antireticular cytotoxic serum | An antiserum specific for cells of the reticuloendothelial system. (05 Mar 2000) |
|---|---|
| cytotoxic | <pharmacology> Chemicals that are directly toxic to cells, preventing their reproduction or growth. Cytotoxic agents can, as a side effect, damage healthy, noncancerous tissues or organs which have a high proportion of actively dividing cells, for example, bone marrow, hair follicles. These side effects limit the amount and frequency of drug administration. (16 Dec 1997) |
| cytotoxic cell | Cells of the immune system that inhibit or help to terminate an immune response, e.g., suppressor macrophages and suppressor T-cells. Synonym: cytotoxic cell. (05 Mar 2000) |
| cytotoxic drugs | <pharmacology> Anti-cancer drugs which act by killing or preventing the division of cells. See: chemotherapy. (13 Nov 1997) |
| cytotoxic reaction | An immunologic (allergic) reaction in which noncytotropic IgG or IgM antibody combines with specific antigen on cell surfaces; the resulting complex initiates the activation of complement which causes cell lysis or other damage, or which, in the absence of complement, may lead to phagocytosis or may enhance T lymphocyte involvement. (05 Mar 2000) |
| cytotoxic T-cell | <haematology, immunology> Subset of T lymphocytes (mostly CD8) responsible for lysing target cells and for killing virus infected cells (in the context of Class I histocompatibility antigens). (18 Nov 1997) |
| cytotoxic t-lymphocyte | A type of CD8 or, less often, CD4 lymphocyte that kills diseased cells infected by a specific virus or other intracellular microbe. CTLs interact with MHC class I receptors (see Major Histocompatibility Complex). On infected cells and have the prime role in cellmediated immunity (see). Cytovene: See: Ganciclovir. (09 Oct 1997) |
| cytotoxic T lymphocyte-specific serine protease | <enzyme> Structural sequence given in first source Registry number: EC 3.4.21.- Synonym: cytotoxic t lymphocyte-specific serine protease ccp I, cytotoxic t lymphocyte specific serine protease ccp II, mast cell protease type II (26 Jun 1999) |
| T cytotoxic cells | Lymphocyte-like effector cells which mediate antibody-dependent cell cytotoxicity. They kill antibody-coated target cells which they bind with their fc receptors. (12 Dec 1998) |
| T-lymphocytes, cytotoxic | Immunised T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (mlc), in vivo during a graft-versus-host (gvh) reaction, or after immunization with an allograft, tumour cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (cml). These cells are distinct from natural killer cells (killer cells, natural) and from killer cells mediating antibody-dependent cell cytotoxicity. (12 Dec 1998) |
| accelerator factor | <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease. Chemical name: Blood-coagulation factor V (12 Dec 1998) |
| acetate replacement factor | <biochemistry> 1,2 dithiolane 3 valeric acid. Regarded as a coenzyme in the oxoglutarate dehydrogenase complex of the citric acid cycle. Involved generally in oxidative decarboxylations of _ keto acids. A growth factor for some organisms. (18 Nov 1997) |
| adrenal weight factor | A postulated substance of adenohypophysial origin responsible for maintenance of the weight of the adrenal cortex. (05 Mar 2000) |
| adrenocorticotropic releasing factor | Hormone produced by hypothalamus that causes pituitary to secrete adrenocorticotropic hormone. (05 Mar 2000) |
| a-factor | <molecular biology> A protein which is found in the bacterial genus Streptomyces that helps start the production of streptomycin and the process of morphological differentiation. It is used in biotechnology to induce these functions in mutant strains of Streptomyces that cannot produce it themselves. (09 Feb 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|